Алопеция в структуре клинических проявлений эндокринопатий: патогенетические и диагностические аспекты

В обзоре рассмотрены ключевые аспекты патогенеза алопеции при патологии эндокринной системы. Продемонстрирована роль целого ряда гормонов, факторов роста, цитокинов и других биологически активных веществ. Показано, что клиническое значение алопеции – весьма распространенного в популяции симптома – далеко не исчерпывается геронтологической проблематикой, и может быть проявлением эндокринопатий. Указанное обстоятельство диктует проведение в целом ряде случаев широкого дифференциально-диагностического поиска, выполнение которого наиболее перспективно при условии реализации мультидисциплинарного подхода с участием эндокринолога, гинеколога, андролога, дерматолога / трихолога и других специалистов.

1. Trüeb R.M. The difficult Hair Loss Patient. Guide to Successful Management of Alopecia and Related Conditions. SpringerInternationalPublishing. 2015; 331 p. DOI: 10.1007/978-3-319-19701-

2. Трихология: диагностика, лечение и уход за волосами. Под ред. Эрнандес Е.И. М. Косметика и Медицина. 2016; 412 с. Trichology: diagnosis, treatment and hair care. Ernandes E.I. M., Cosmetics and Medicine. 2016; 412 p. [In Russian].

3. Batrinos M.L. The endocrinology of baldness. Hormones. 2014; 13(2):197-212. DOI: 10.1007/BF03401334.

4. Hamilton J.B. Effect of castration in adolescent and young adult upon further changes in the proportion of bare and hairy scalp. J ClinEndocrinolMetab. 1960; 20:1309-18. DOI:10.1210/jcem-20-10-1309.

5. Sinclair R.D. Male pattern androgenetic alopecia BMJ. 1998; 317(7162): 865–869. DOI: 10.1136/bmj.317.7162.865.

6. Herskovitz I., Tosti A. Female pattern hair loss. Int J EndocrinolMetab. 2013; 11(4):e9860. DOI:10.5812/ijem.9860.

7. Glaser R.L., Dimitrakakis C., Messenger A.G. Improvement in scalp hair growth in androgen-deficient women treated with testosterone: a questionnaire study. Br J Dermatol. 2012; 166(2):274–278. DOI: 10.1111/j.1365-2133.2011.10655.x.

8. Grymowicz M., Rudnicka E., Podfigurna A., et al. Hormonal Effects on Hair Follicles Int J Mol Sci. 2020; 21(15): 5342. DOI: 10.3390/ijms21155342.

9. Thornton M.J. The biological actions of estrogens on skin. Exp Dermatol.2002; 11(6):487-502. DOI: 10.1034/j.1600-0625.2002.110601.x.

10. Shi-Sheng Zhou Da Li, Yi-Ming Zhou, et al. The skin function: a factor of anti-metabolic syndrome. DietologMetabSyndr. 2012;4(1):15. DOI: 10.1186/1758-5996-4-15.

11. Gallicchio L., Calhoun C., Helzlsouer K.J. Aromatase inhibitor therapy and hair loss among breast cancer survivors. Breast Cancer Res Treat. 2013; 142(2):435-43. DOI: 10.1007/s10549-013-2744-2.

12. Riedel-Baima B., Riedel A. Female pattern may be triggered by oestrogen to androgen ratio. EndocrRegul. 2008; 42(1):13-6.

13. Langlade C., Gouverneur A., Bosco-Lévy P., et al. Adverse events reported for Mirena levonorgestrel-releasing intrauterine device in France and impact of media coverage. Br J Clin Pharmacol. 2019; 85(9): 2126–2133. DOI: 10.1111/bcp.14027.

14. Fabbriocini G., Cantelli M., Masara A., et al. Female pattern hair loss: A clinical, pathophysiologic, and therapeutic review. Int J Womens Dermatol. 2018; 4(4): 203–211. DOI: 10.1016/j.ijwd.2018.05.001.

15. Riux C., Pelissier C., Fechtenbaum J., et al. Randomized, doublemasked, 2-year comparison of tibolone with 17beta-estradiol and norethindrone acetate in preventing postmenopausal bone loss. Osteoporos Int. 2002;13(3):241-8. DOI: 10.1007/s001980200021.

16. Brough K.R., Torgerson R.R. Hormonal therapy in female pattern hair loss. Int J Women Dermatol. 2017; 3(1):53-57. DOI: 10.1016/j. ijwd.2017.01.001.

17. Hagenaars S.P., Hill W.D., Harris S.E., et al. Genetic prediction of male pattern baldness. PLOS Genetics. 2017; 13(2):e1006594. DOI:10.1371/journal.pgen.1006594.

18. Cassidenti D.L., Paulson R.J., et al. Effectsofsexsteroids on skin 5 alpha-reductaseactivity in vitro. ObstetGynecol. 1991;78(1):103-7.

19. Oettel M., Mukhopadhyay A.K. Progesterone: the forgotten hormone in men? Aging Male. 2004; 7(3):236-57. DOI: 10.1080/13685530400004199.

20. Serafini P., Lobo R.A. Prolactin modulates peripheral androgen metabolism. FertilSteril. 1986; 45(1):41-6. DOI: 10.1016/S0015-0282(16)49094-1.

21. Tirgar-Tabari S., Sharbatdaran M., Manafi-Akham S., et al. Hyperprolactinemia and hirsutism in patients without polycystic ovary syndrome Int J Trichology. 2016; 8(3):130–134. DOI: 10.4103/0974- 7753.188998.

22. Trüeb R.M.Hormones and hair growth. Hautarzt. 2010; 61(6):487-95. DOI: 10.1007/s00105-009-1890-2.

23. Lutz G. Hair loss and hyperprolactinemia in women. Dermatoendocrinol. 2012; 4(1): 65–71. DOI: 10.4161/derm.19472.

24. Gaspar E., Nguyen-Thi K.T., Hardenbicker C., et al. Thyrotropin-releasing hormone selectively stimulates human hair follicle pigmentation. J Invest Dermatol. 2011; 131(12):2368-77. DOI: 10.1038/jid.2011.221.

25. Paus R., Langan E.A., Vidali S., et al. Neuroendocrinology of the hair follicle: principles and clinical perspectives. Trends in Molecular Medicine. 2014; 20(10):559-70. DOI: 10.1016/j.molmed.2014.06.002.

26. Contreras-Jurado C., Lorz C., Garcia-Serrano L., et al. Thyroid hormone signaling controls hair follicle stem cell function. Mol Biol Cell. 2015; 26(7):1263–1272. DOI: 10.1091/mbc.E14-07-1251.

27. Vincent M., Yogiraj K.A. Descriptive study of alopecia patterns and their relation to thyroid dysfunction. Int J Trichology. 2013; 5(1): 57–60. DOI: 10.4103/0974-7753.114701.

28. Siah T.W., Muir-Green L., Shapiro J. Female Patttern Hair Loss: A Retrospective Study in a Tertiary Refferal Center. Int. J Trichology. 2016; 8(2):57-61. DOI: 10.4103/0974-7753.188033.

29. Jagadish K, Kumar M.S., Kumar T.S., et al. Diffuse scalp hair loss due to levothyroxine overdose. Indian Dermatol Online J. 2015; 6(Suppl 1):S58–S60. DOI: 10.4103/2229-5178.171054.

30. Pike J.W., Christakos S. Biology and mechanism of action of the vitamin D hormone. EndocrinolMetabClin North Am. 2017; 46(4):815-843. DOI: 10.1016/j.ecl.2017.07.001.

31. Yao X, Lawson M.S., Fuhua Xu, et al. Vitamin D receptor expression and potential role of vitamin D on cell proliferation and steroidogenesis in goat ovarian granulosa cells. Theriogenology. 2017; 15(102):162-173. DOI: 10.1016/j.theriogenology.2017.08.002.

32. Hanif F., Ilyas N., Qamar T. Association of vitamin D deficiency with hyperandrogegism in females with polycystic ovarian syndrome. International Journal of Clinical and Biomedical Research. 2018; 4(2):31-34. DOI: 10.5455/ijcbr.2018.42.07.

33. Lundqvist J. Vitamin D as a regulator of steroidogenic enzymes. F1000research. 2014; 3:155. DOI: 10.12688/f11000research.4714.1.

34. Bakhshalizadeh S., Amidi F., Alleyassin A., et al. Modulation of steroidogenesis by vitamin D3 in granulosa cells of the mouse model of polycystic ovarian syndrome. SystBiolReprod Med. 2017; 63(3):150-161. DOI: 10.1080/19396368.2017.1296046.

35. Rasheed H., MahgoubD.,HegazyR., et al. Serum ferritin and vitamin D in female pattern hair loss: do they play the role? Skin Pharmacol Physiol. 2013; 26(2):101-7. DOI: 10.1159/000346698.

36. Amor K.T., Rashid R.M., Mirmirani P. Does D matter? The role of vitamin D in hair disorders and hair follicle cycling. Dermatol online J. 2010; 16(2): 3.

37. Kong J., Li X.J., Gavin D., et al. Targeted expression of human vitamin D receptor in the skin promotes the initiation of the postnatal hair follicle cycle and rescues the alopecia in vitamin D receptor null mice. J Invest Dermatol. 2002; 118(4):631-638. DOI: 10.1046/j.1523-1747.2002.01727.x.

38. Parikh G., Varadinova M., Suwandhi P., et al. Vitamin D regulates steroidogenesis and insulin-like growth factor binding protein-1 (IGFBP-1) production in human ovarian cells. HormMetab Res. 2010; 42(10):754-7. DOI:10.1055/s-0030-1262837.

39. Dankers W., Colin E.M., van Hamburg J.P., et al. Vitamin D Autoimmunity: molecular mechanism and therapeutic potential. Front Immunol. 2016; 7: 697. DOI: 10.3389/fimmu.2016.00697.

40. Daroach M., Narang T., Saikia U.N., et al. Correlation of vitamin D and vitamin D receptor expression in patients with alopecia areata: a clinical paradigm. Int J Dermatol. 2018; 57(2):217-222. DOI: 10.1111/ijd.13851.

41. Malloy P.J., Feldman D. The role of vitamin D receptor mutations in the development of alopecia. Mol Cell Endocrinol. 2011; 347(1-2):90-96. DOI: 10.1016/j.mce.2011.05.045.

42. Gerkowicz A., Chyl-Surdacka K., Krasowska D., et al.The role of vitamin D in non-scarring alopecia. Int J Mol Sci. 2017; 18(12):2653. DOI: 10.3390/ijms18122653.

43. Philpott M.P., Sanders D.A., Kealey T. Effects of insulin and insulin-like growth factors on cultured human hair follicles: IGF-I at physiologic concentrations is an important regulator of hair follicle growth in vitro. Journal of Investigative Dermatology. 1994; 102(6): 857-61. DOI: 10.1111/1523-1747.ep12382494.

44. Saleh D., Naga S.S.Y., Cook C. Hypertrichosis. StatPearls Publishing LLC., Sept. 12, 2019. PMID: 30521275.

45. Santos Z., Avci P., Hamblin M.R. Drug discovery for alopecia: gone today, hair tomorrow. Expert Opin Drug Discov. 2015; 10(3):269–292. DOI: 10.1517/17460441.2015.1009892.

46. Sigalos J.T., Pastuszak A.W., Allison A., et al. Growth hormone secretagogue treatment in hypogonadal men raises serum insulinlike growth factor-1 levels. Am J Mens Health. 2017; 11(6):1752-1757. DOI: 10.1177/1557988317718662.

47. Kayampilly P.P., Wanamaker B.L., Stewart J.A.,et al. Stimulatory Effect of Insulin on 5α-Reductase Type 1 (SRD5A1) Expression through an Akt-Dependent Pathway in Ovarian Granulosa Cells. Endocrinol. 2010; 151(10):5030–5037. DOI: 10.1210/en.2010-0444.

48. Mumcuoglu C., Ekmekci T.R., Ucak S. The investigation of insulin resistance and metabolic syndrome in male patients with earlyonset androgenetic alopecia Eur J Dermatol.2011; 21(1):79-82. DOI: 10.1684/ejd.2010.1193.

49. Starka L., Duskova M., Cermakova I., et al.Premature androgenic alopecia and insulin resistance. Male equivalent of polycystic ovary syndrome? EndocrRegul. 2005; 39(4):127-131.

50. Cannarella R., Condorelli R.A., Dall’Oglio F., et al. Increased DHEAS and Decreased Total Testosterone Serum Levels in a Subset of Men with Early-Onset Androgenetic Alopecia: Does a Male PCOS-Equivalent Exist? Int J Endocrinol. 2020: 1942126. DOI: 10.1155/2020/1942126.

51. Karatas F., Sahin S., Sever A.R, et al. Management of hair loss associated with endocrine therapy in patients with breast cancer: an overview. Springerplus. 2016; 5:585. DOI: 10.1186/s40064-016-2216-3.

52. Sawaya М.Е., Price V.H. Different levels of 5alpha-reductase type I and II, aromatase, and androgen receptor in hair follicles of women and men with androgenetic alopecia. J Invest Dermatol. 1997; 109(3):296-300. DOI: 10.1111/1523-1747.ep12335779.

53. Lie C., Liew C.F., Oon H.H. Alopecia and the metabolic syndrome. Clin Dermatol. 2018; 36(1):54-61. DOI: 10.1016/j.clindermatol.2017.09.009.

54. Bakry O.A., Shoeib M.A., Shaffiee M.K., et al Androgenetic alopecia, metabolic syndrome, and insulin resistance: Is there any association? A case-control study. Indian Dermatol Online J. 2014; 5(3):276-81. DOI: 10.4103/2229-5178.137776.

55. Cakir E. The association between metabolic syndrome components and hair loss both male and female individuals. Hair Ther Transplant.2013; 3:110. DOI: 10.4172/2167-0951.1000110.

56. Jingwen Ma Youyu Sheng, Zhengyin Lao, et al. Hyperuricemia is associated with androgenetic alopecia in men: A cross-sectional case-control study J Cosmet Dermatol. 2020;19(11):3122-3126. DOI: 10.1111/jocd.13401.

57. Vinay K., Sawatkar G.U., Dogra S. Hair manifestations of endocrine diseases: A brief review. Indian J Dermatol Venerol Leprol. 2018; 84(5):528-538. DOI: 10.4103/ijdvl.IJDVL_671_17.

58. Robert S., English Jr. A hypothetical pathogenesis model for androgenic alopecia: clarifying the dihydrotestosterone paradox and rate-limiting recovery factors. Med Hypotheses. 2018; 111: 73-81. DOI: 10.1016/j.mehy.2017.12.027.

59. Tilwani M.R., Dogra N.K., Dogra D., et al. Androgenetic alopecia as a maker of metabolic syndrome in male patients of androgenetic alopecia: a hospital-based case control study. Int J Res Med Sci. 2017; 5(2):601-606. DOI: 10.18203/2320-6012.ijrms20170159.

60. Dharam Kumar K.C., Yadalla Hari Kishan Kumar, Vivekananda Neladimmanahally. Association of Androgenetic Alopecia with Metabolic Syndrome: A Case–control Study on 100 Patients in a Tertiary Care Hospital in South India. Indian J Endocrinol Metab. 2018; 22(2):196-199. DOI:10.4103/ijem.IJEM_650_17.

61. Caihong Xin, Xin Sun, Li Lu, et al. Increased Incidence of Thyroid Disease in Patients with Alopecia Areata: A Systematic Review and Meta-Analysis. Dermatology.2020;236(3):251-254. DOI: 10.1159/000502025.

62. Bhat Y.J, Saquib N., Latif I., et al. Female Pattern Hair Loss— An Update. IndianDermatol. OnlineJ. 2020; 11(4):493-501. DOI: 10.4103/idoj.IDOJ_334_19.